Objectives To assess whether a single instance of low-level viraemia (LLV) is associated
with the presence of drug resistance mutations (DRMs) and predicts subsequent virological …

Background Effective ART is crucial for combating the HIV pandemic. Clinically, plasma viral
load monitoring to achieve virological suppression is the guide for an optimal ART. The …

Objectives We implemented the WHO cross-sectional survey protocol to determine rates of
HIV viral load (VL) suppression (VLS), and weighted prevalence, predictors and patterns of …

Background. As antiretroviral therapy (ART) programs in sub-Saharan Africa mature,
increasing numbers of persons with human immunodeficiency virus (HIV) infection will …

Background: We assessed risk factors for viremia and drug resistance among long-term
recipients of antiretroviral therapy (ART) in South Africa. Methods: In 2008, we conducted a …

Objectives There is conflicting evidence on the impact of pre-existing HIV drug resistance
mutations (DRMs) in patients infected with non-B subtype virus. Methods We performed a …

Objectives To determine the feasibility of HIV genotyping at low-level viraemia (LLV) using
an in-house assay in a South African population and the prevalence, as well as the clinical …

Purpose Monitoring HIV-1 drug resistance mutations (DRM) in treated patients on
combination antiretroviral therapy (cART) with a detectable HIV-1 viral load (VL) is important …

Objectives Emerging resistance to antiretroviral drugs may jeopardize the achievements of
improved access to ART. We compared the prevalence of different resistance mutations in …

Background Drug-resistance mutations (DRAM) are frequently selected in patients with
virological failure defined as viral load (pVL) above 500 copies/ml (c/mL), but few resistance …